In a recent study, researchers discovered that naturally occurring fat-based molecules in the human body may play a significant role in reducing inflammation and regulating the immune system. This could eventually lead to new treatments for diseases connected to chronic inflammation, like arthritis and heart disease.
The molecules, called epoxy-oxylipins, are produced from fats within the body and act as a natural monitor of immune activity.
Scientists found that these molecules help prevent the buildup of a specific type of immune cell known as intermediate monocytes.
These white blood cells normally help the body fight infections and repair damaged tissues. However, when active for too long or in large numbers, they can keep the immune system overstimulated, leading to chronic inflammation.
Chronic inflammation is a major health concern because it has been linked to serious diseases like rheumatoid arthritis and cardiovascular disease.
Due to this, scientists have been searching for ways to control inflammation without weakening the immune system’s ability to protect the body.
To better understand how epoxy-oxylipins work in humans, researchers conducted an experiment where healthy participants received a small injection of dead E. coli bacteria in the forearm.
Although the bacteria was inactive and unable to cause infection, the injection triggered a temporary inflammatory response to what happens when the body experiences injury or infection. As a result, volunteers developed mild symptoms like redness, swelling, heat and pain around the injection site.
In the study, the participants were divided into two groups to test a drug that affects the levels of epoxy-oxylipins in the body. One group received the drug before the inflammatory reaction began, while the second group received the drug several hours after inflammation had already started.
The drug works by blocking an enzyme called soluble epoxide hydrolase, which breaks down epoxy-oxylipins. By blocking this enzyme, the body can maintain higher levels of these protective molecules.
The results showed that volunteers who received the drug had increased levels of epoxy-oxylipins and experienced faster relief from pain.
Researchers also observed significantly lower levels of intermediate monocytes in the blood and tissue of participants who received the treatment.
Interestingly, the medication did not significantly change the visible signs of inflammation, but it did reduce the underlying immune activity that can lead to long-term damage.
Scientists believe this finding may lead to new types of anti-inflammatory treatments.
Unlike many current medications that broadly suppress the immune system, therapies based on epoxy-oxylipins could help restore balance to the immune response while still allowing the body to fight infections efficiently.
Although more research and clinical trials will be needed to confirm these findings, the study provides valuable insight into how the body naturally regulates inflammation.
In the future, drugs that enhance these protective fat-based molecules may offer better ways to treat chronic inflammatory diseases and improve quality of life for many patients.
